Market Research Logo

Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2017-2021

Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2017-2021

About Hematopoietic Stem Cells Transplantation (HSCT)

HSCT is the most widely used stem-cell therapy, where blood from umbilical cord is used. Research is being undertaken to discover various sources (such as cord blood cells, bone marrow, and peripheral blood cells) of hematopoietic stem cells to treat various disorders like hematological malignancies, blood related disorders (leukemia and lymphoma), neurodegenerative diseases and conditions such as heart disease, diabetes, and other conditions.

Stem-cell therapy has become controversial after developments in isolating and culturing of embryonic stem cells. Somatic cell nuclear transfer is the technique used in embryonic stem cell research to create stem cells and induced pluripotent stem cells. This controversy is related to abortion policies and human cloning. However, the changing regulatory landscape in countries like the US and Japan may help to accelerate the clinical trials.

Technavio’s analysts forecast the global hematopoietic stem cells transplantation (HSCT) market to grow at a CAGR of 5.75% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global hematopoietic stem cells transplantation (HSCT) market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of hematopoietic stem cells transplantation (HSCT).

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AllCells
  • Lonza
  • Merck
  • Sanofi
Other prominent vendors
  • Athersys
  • Beike Biotechnology
  • BioTime
  • bluebird bio
  • Caladrius
  • Cellular Biomedicine Group
  • Cellular Dynamics International (a subsidiary of Fujifilm)
  • Cesca Therapeutics
  • CHA Biotech
  • CORESTEM
  • Gamida Cell
  • Global Stem Cells Group
  • Hemostemix
  • Histocell
  • Mesoblast
  • TiGenix
  • Translational Biosciences (a subsidiary of Medistem Panama)
Market driver
  • Rising number of HSCT
  • For a full, detailed list, view our report
Market challenge
  • High cost of HSCT
  • For a full, detailed list, view our report
Market trend
  • Growing demand for personalized medicine
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2017-2021

Technavio recognizes the following companies as the key players in the global hematopoietic stem cells transplantation (HSCT) market: AllCells, Lonza, Merck, and Sanofi

Other Prominent Vendors in the market are: Athersys, Beike Biotechnology, BioTime, bluebird bio, Caladrius, Cellular Biomedicine Group, Cellular Dynamics International (a subsidiary of Fujifilm), Cesca Therapeutics, CHA Biotech, CORESTEM, Gamida Cell, Global Stem Cells Group, Hemostemix, Histocell, Mesoblast, TiGenix, and Translational Biosciences (a subsidiary of Medistem Panama).

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Growing demand for personalized medicine. Personalized medicine can offer treatments based on the patient's characteristics, needs, and preferences. Therefore, research organizations are extensively exploring ways to develop personalized treatments by using mesenchymal stem cells owing to its higher benefits. Their benefits include low risk of immune rejection, no requirement of embryonic stem cell, limited need for anti-rejection drugs, low risk of graft rejection, and less chance of developing GvHD.”

According to the report, one of the major drivers for this market is Rising number of HSCT. Owing to the efficacy of HSCT, their demand is ever growing for treating leukemia, lymphoma, immune-deficiency illnesses, hemoglobinopathies, congenital metabolic defects, and myelodysplastic and myeloproliferative syndromes. Further, over the period of time, it has been observed that the allogenic HSCT outweighs the autologous transplants despite allogenic being more susceptible to GvHD.

Further, the report states that one of the major factors hindering the growth of this market is High cost of HSCT. The number of HSCT transplant is expected to increase due to continuous advancements in the transplantation technology, emergence of new indications, supportive care practices, and availability of alternative graft source. In 2009, HSCT was one of the top ten procedures associated with increased hospital cost. The overall cost associated with HSCT has shown 85% increase between 2004 and 2007, which is from $694 million to $1.3 billion.

Companies Mentioned

AllCells, Lonza, Merck, Sanofi, Athersys, Beike Biotechnology, BioTime, bluebird bio, Caladrius, Cellular Biomedicine Group, Cellular Dynamics International (a subsidiary of Fujifilm), Cesca Therapeutics, CHA Biotech, CORESTEM, Gamida Cell, Global Stem Cells Group, Hemostemix, Histocell, Mesoblast, TiGenix, and Translational Biosciences (a subsidiary of Medistem Panama).

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Developments in stem cell research
      • Table Global HSCT market snapshot
  • HSCT: An overview
    • Hematopoietic stem cell transplantation
      • Table History of HSCT
    • Source of hematopoietic cells
      • Table HSCT sources
    • Types of transplant
      • Table Types of transplant
    • The HSCT procedure
  • Pipeline
    • Table Pipeline snapshot based on vendors
    • Table Pipeline snapshot based on type of intervention
    • Table Pipeline snapshot based on different-phases
    • Table Pipeline landscape
    • Table Purpose of trial
  • Market landscape
    • Market overview
      • Table Global HSCT market snapshot 2016
      • Table Global HSCT market 2016-2021 ($ millions)
      • Table Opportunity analysis in global HSCT market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by therapeutic application
    • Table Global HSCT market segmentation by therapeutic application
    • Table Global HSCT market share by therapeutic application
    • AML
    • ALL
    • HL
    • NHL
    • CML
    • MM
    • Others
      • Table HSCT for other diseases
  • Market segmentation by transplant
    • Table Global HSCT market segmentation by transplant type
    • Table Global HSCT market share by transplant type 2016
    • Global autologous HSCT market
      • Table Global autologous HSCT market 2016-2021 ($ millions)
      • Table Opportunity analysis of global autologous HSCT market
    • Global allogenic HSCT market
      • Table Global allogenic HSCT market 2016-2021 ($ millions)
      • Table Opportunity analysis of global allogeneic HSCT market
  • Geographical segmentation
    • Table Global HSCT market by geography 2016 and 2021
    • Table Global HSCT market revenue by geography 2016-2021 ($ millions)
    • Table Global HSCT market by geography 2016-2021 (%)
    • HSCT market in EMEA
      • Table Market scenario in EMEA
      • Table HSCT market in EMEA 2016-2021 ($ millions)
    • HSCT market in Americas
      • Table Market scenario in Americas
      • Table HSCT market in Americas 2016-2021 ($ millions)
    • HSCT market in APAC
      • Table Market scenario in APAC
      • Table HSCT market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Snapshot of transplant scenario from 1984-2007
      • Table Funding for stem cell research 2013-2018
      • Table Details of European Commission funding
    • Market challenges
      • Table Long-term complications associated with HSCT
      • Table Symptoms of GvHD
  • Market trends
    • Growing demand for personalized medicine
    • Decreasing morbidity and mortality rate
      • Table Risk of mortality in age-matched general population and HSCT patient with two years after allogenic transplant
    • Advent of cord blood banking
    • Increasing focus in RIC regimen
      • Table Benefits of using RIC
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global HSCT market 2016
  • Key vendor analysis
    • AllCells
      • Table AllCells: Key highlights
      • Table AllCells: Strength assessment
      • Table AllCells: Strategy assessment
      • Table AllCells: Opportunity assessment
    • Lonza
      • Table Lonza: Key highlights
      • Table Lonza: Strength assessment
      • Table Lonza: Strategy assessment
      • Table Lonza: Opportunity assessment
    • Merck
      • Table Merck: Key highlights
      • Table Merck: Strength assessment
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
    • Sanofi
      • Table Sanofi: Key highlights
      • Table Sanofi: Strength assessment
      • Table Sanofi: Strategy assessment
      • Table Sanofi: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report